Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Pyridostigmine Bromide Tablets USP, 60 mg. The estimated sales in 2015 for Pyridostigmine Bromide Tablets USP which is used in the treatment of various neurological disorders is $27.9 million as per IMS.
The group now has 100 approvals and has so far filed over 260 AND As since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.
